Performance of different CT enhancement quantification methods as predictors of pancreatic cancer recurrence after upfront surgery

The prognosis of pancreatic cancer (PDAC) after tumor resection remains poor, mostly due to a high but variable risk of recurrence. A promising tool for improved prognostication is the quantification of CT tumor enhancement. For this, various enhancement formulas have been used in previous studies. However, a systematic comparison of these formulas is lacking. In the present study, we applied twenty-three previously published CT enhancement formulas to our cohort of 92 PDAC patients who underwent upfront surgery. We identified seven formulas that could reliably predict tumor recurrence. Using these formulas, weak tumor enhancement was associated with tumor recurrence at one and two years after surgery (p ≤ 0.030). Enhancement was inversely associated with adverse clinicopathological features. Low enhancement values were predictive of a high recurrence risk (Hazard Ratio ≥ 1.659, p ≤ 0.028, Cox regression) and a short time to recurrence (TTR) (p ≤ 0.027, log-rank test). Some formulas were independent predictors of TTR in multivariate models. Strikingly, almost all of the best-performing formulas measure solely tumor tissue, suggesting that normalization to non-tumor structures might be unnecessary. Among the top performers were also the absolute arterial/portal venous tumor attenuation values. These can be easily implemented in clinical practice for better recurrence prediction, thus potentially improving patient management.

Authors

Institutions

Publication Details

Journal
Scientific Reports
Published
2024-08-26
DOI
https://doi.org/10.1038/s41598-024-70441-3
Citations
2
Primary Topic
Pancreatic and Hepatic Oncology Research
Type
article
Field-Weighted Citation Impact
0.57

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Performance of different CT enhancement quantification methods as predictors of pancreatic cancer recurrence after upfront surgery

Thilo Hackert, Sherif Mohamed, Matthias M. Gaida, Philipp Mayer et al.
2 citations
Scientific Reports
Pancreatic and Hepatic Oncology Research
0.57
article

Performance of different CT enhancement quantification methods as predictors of pancreatic cancer recurrence after upfront surgery

Thilo Hackert, Sherif Mohamed, Matthias M. Gaida, Philipp Mayer, Verena Steinle, Tobias Nonnenmacher, Alina Barlemann, Miriam Klauß, Hans‐Ulrich Kauczor, Michelle Güttlein, Martin Loos
article en
2 citations

Abstract

The prognosis of pancreatic cancer (PDAC) after tumor resection remains poor, mostly due to a high but variable risk of recurrence. A promising tool for improved prognostication is the quantification of CT tumor enhancement. For this, various enhancement formulas have been used in previous studies. However, a systematic comparison of these formulas is lacking. In the present study, we applied twenty-three previously published CT enhancement formulas to our cohort of 92 PDAC patients who underwent upfront surgery. We identified seven formulas that could reliably predict tumor recurrence. Using these formulas, weak tumor enhancement was associated with tumor recurrence at one and two years after surgery (p ≤ 0.030). Enhancement was inversely associated with adverse clinicopathological features. Low enhancement values were predictive of a high recurrence risk (Hazard Ratio ≥ 1.659, p ≤ 0.028, Cox regression) and a short time to recurrence (TTR) (p ≤ 0.027, log-rank test). Some formulas were independent predictors of TTR in multivariate models. Strikingly, almost all of the best-performing formulas measure solely tumor tissue, suggesting that normalization to non-tumor structures might be unnecessary. Among the top performers were also the absolute arterial/portal venous tumor attenuation values. These can be easily implemented in clinical practice for better recurrence prediction, thus potentially improving patient management.

Scientific ReportsVol. 14(1)
Universität Hamburg (DE), Johannes Gutenberg University Mainz (DE), Heidelberg University (DE), University Hospital Heidelberg (DE), University Medical Center of the Johannes Gutenberg University Mainz (DE), University Medical Center Hamburg-Eppendorf (DE), Translationale Onkologie an der Universitätsmedizin der Johannes Gutenberg-Universität Mainz (DE), University Medical Centre Mannheim (DE)
Universitätsklinikum Heidelberg
No poverty
Openalex Percentile: Top 28%
Pancreatic and Hepatic Oncology Research
0.57
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.